Modulation of STAT3 and STAT5 activity rectifies the imbalance of Th17 and Treg cells in patients with acute coronary syndrome

Clinical Immunology

Volumn 157, Issue 1, 2015, Pages 65-77

  Zheng, Yingxia ^a   Wang, Zhihao ^a   Deng, Lin ^a   Zhang, Guanghui ^a   Yuan, Xiangliang ^a   Huang, Liya ^a   Xu, Weiping ^a   Shen, Lisong ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute coronary syndrome; STAT3; STAT5; Th17 cells; Treg cells

Indexed keywords

FEDRATINIB; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE 2; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; TRANSCRIPTION FACTOR FOXP3; CYTOKINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; ELECTROPORATION; FEMALE; FLOW CYTOMETRY; GENE LOCUS; GENE OVEREXPRESSION; GENE SILENCING; HEART EJECTION FRACTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROENVIRONMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; RNA INTERFERENCE; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; WESTERN BLOTTING; BLOOD; CYTOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; STABLE ANGINA PECTORIS; UPREGULATION;

ACUTE CORONARY SYNDROME; ANGINA, STABLE; CELL DIFFERENTIATION; CYTOKINES; FLOW CYTOMETRY; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; UP-REGULATION;

EID: 84921461763     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.12.012     Document Type: Article

References (43)

1. Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349:1436-1442.
2. Klingenberg R., Hansson G.K. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur. Heart J. 2009, 30:2838-2844.
3. de Boer O.J., van der Wal A.C., Houtkamp M.A., Ossewaarde J.M., Teeling P., Becker A.E. Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumonia. Cardiovasc. Res. 2000, 48:402-408.
4. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3893-3897.
5. Cheng X., Yu X., Ding Y.J., Fu Q.Q., Xie J.J., Tang T.T., Yao R., Chen Y., Liao Y.H. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin. Immunol. 2008, 127:89-97.
6. Ma Y., Yuan X., Deng L., Xu W., Zheng Y., Yue C., Zhang G., Xie F., Yang Y.H., Gantier M.P., Liu J., Xu D., Shen L. Imbalanced frequencies of Th17 and Treg cells in acute coronary syndromes are mediated by IL-6-STAT3 signaling. PLoS One 2013, 8:e72804.
7. Mertens C., Darnell J.E. SnapShot: JAK-STAT signaling. Cell 2007, 131:612.
8. Shuai K., Liu B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 2003, 3:900-911.
9. Takahashi R., Nishimoto S., Muto G., Sekiya T., Tamiya T., Kimura A., Morita R., Asakawa M., Chinen T., Yoshimura A. SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as INF-γ and IL-17A production. J. Exp. Med. 2011, 208:2055-2067.
10. Yang X.O., Panopoulos A.D., Nurieva R., Chang S.H., Wang D., Watowich S.S., Dong C. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 2007, 282:9358-9363.
11. Gardner P.J., Joshi L., Lee R.W., Dick A.D., Adamson P., Calder V.L. SIRT1 activation protects against autoimmune T cell-driven retinal disease in mice via inhibition of IL-2/Stat5 signaling. J. Autoimmun. 2013, 42:117-129.
12. Murawski M.R., Litherland S.A., Clare-Salzler M.J., Davoodi-Semiromi A. Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis. Ann. N. Y. Acad. Sci. 2006, 1079:198-204.
13. Vogtenhuber C., Bucher C., Highfill S.L., Koch L.K., Goren E., Panoskaltsis-Mortari A., Taylor P.A., Farrar M.A., Blazar B.R. Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses. Blood 2010, 116:466-474.
14. Yao Z., Kanno Y., Kerenyi M., Stephens G., Durant L., Watford W.T., Laurence A., Robinson G.W., Shevach E.M., Moriggl R., Hennighausen L., Wu C., O'Shea J.J. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 2007, 109:4368-4375.
15. Nie H., Zheng Y., Li R., Guo T.B., He D., Fang L., Liu X., Xiao L., Chen X., Wan B., Chin Y.E., Zhang J.Z. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat. Med. 2013, 19:322-328.
16. Pardanani A., Gotlib J.R., Jamieson C., Cortes J.E., Talpaz M., Stone R.M., Silverman M.H., Gilliland D.G., Shorr J., Tefferi A. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J. Clin. Oncol. 2011, 29:789-796.
17. Furqan M., Mukhi N., Lee B., Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark. Res. 2013, 1:5.
18. Wernig G., Kharas M.G., Okabe R., Moore S.A., Leeman D.S., Cullen D.E., Gozo M., McDowell E.P., Levine R.L., Doukas J., Mak C.C., Noronha G., Martin M., Ko Y.D., Lee B.H., Soll R.M., Tefferi A., Hood J.D., Gilliland D.G. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008, 13:311-320.
19. Xu L., Kitani A., Stuelten C., McGrady G., Fuss I., Strober W. Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. Immunity 2010, 33:313-325.
20. Zorn E1, Nelson E.A., Mohseni M., Porcheray F., Kim H., Litsa D., Bellucci R., Raderschall E., Canning C., Soiffer R.J., Frank D.A., Ritz J. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006, 108:1571-1579.
21. Liuzzo G., Trotta F., Pedicino D. Interleukin-17 in atherosclerosis and cardio vascular disease the good, the bad, and the unknown. Eur. Heart J. 2013, 34:556-559.
22. Mor A., Luboshits G., Planer D., Keren G., George J. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur. Heart J. 2006, 27:2530-2537.
23. Babon J.J., Varghese L.N., Nicola N.A. Inhibition of IL-6 family cytokines by SOCS3. Semin. Immunol. 2014, 26:13-19.
24. Sansone P., Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J. Clin. Oncol. 2012, 30:1005-1014.
25. Boniface Katia, Blom Bianca, Liu Yong-Jun, de Waal Malefyt René From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol. Rev. 2008, 226:132-146.
26. Betts B.C., Abdel-Wahab O., Curran S.A., St Angelo E.T., Koppikar P., Heller G., Levine R.L., Young J.W. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood 2011, 118:5330-5339.
27. Hori S. c-Rel: a pioneer in directing regulatory T-cell lineage commitment. Eur. J. Immunol. 2010, 40:664-667.
28. Kitoh A., Ono M., Naoe Y., Ohkura N., Yamaguchi T., Yaguchi H., Kitabayashi I., Tsukada T., Nomura T., Miyachi Y., Taniuchi I., Sakaguchi S. Indispensable role of the Runx1-Cbfbeta transcription complex for in vivo-suppressive function of FoxP3+ regulatory T cells. Immunity 2009, 31:609-620.
29. Takimoto T., Wakabayashi Y., Sekiya T., Inoue N., Morita R., Ichiyama K., Takahashi R., Asakawa M., Muto G., Mori T., Hasegawa E., Saika S., Hara T., Nomura M., Yoshimura A. Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated regulation of regulatory T plasticity and Th1 development. J. Immunol. 2010, 185:842-855.
30. Zheng Y., Josefowicz S., Chaudhry A., Peng X.P., Forbush K., Rudensky A.Y. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010, 463:808-812.
31. Laurence A., Amarnath S., Mariotti J., Kim Y.C., Foley J., Eckhaus M., O'Shea J.J., Fowler D.H. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity 2012, 37:209-222.
32. Long S.A., Cerosaletti K., Bollyky P.L., Tatum M., Shilling H., Zhang S., Zhang Z.Y., Pihoker C., Sanda S., Greenbaum C., Buckner J.H. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010, 59:407-415.
33. Koenen H.J., Smeets R.L., Vink P.M., van Rijssen E., Boots A.M., Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008, 112:2340-2352.
34. Zheng Y., Wang Z., Deng L., Yuan X.L., Ma Y., Zhang G., Gantier M.P., Liu J.P., Shen L., Xu D. Osteopontin promotes inflammation in patients with acute coronary syndrome through its activity on IL-17 producing cells. Eur. J. Immunol. 2012, 42:2803-2814.
35. Kryczek I., Wu K., Zhao E., Wei S., Vatan L., Szeliga W., Huang E., Greenson J., Chang A., Rolinski J., Radwan P., Fang J., Wang G., Zou W. IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J. Immunol. 2011, 186:4388-4395.
36. Hori S. Developmental plasticity of Foxp3+ regulatory T cells. Curr. Opin. Immunol. 2010, 22:575-582.
37. Xu L., Kitani A., Fuss I., Strober W. Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J. Immunol. 2007, 178:6725-6729.
38. Gao Q., Jiang Y., Ma T., Zhu F., Gao F., Zhang P., Guo C., Wang Q., Wang X., Ma C., Zhang Y., Chen W., Zhang L. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J. Immunol. 2010, 185:5820-5827.
39. Zhu F., Wang Q., Guo C., Wang X., Cao X., Shi Y., Gao F., Ma C., Zhang L. IL-17 induces apoptosis of vascular endothelial cells: a potential mechanism for human acute coronary syndrome. Clin. Immunol. 2011, 141:152-160.
40. del Rosario Espinoza Mora M1, Böhm M., Link A. The Th17/Treg imbalance in patients with cardiogenic shock. Clin. Res. Cardiol. 2014, 103:301-313.
41. Taleb S., Romain M., Ramkhelawon B., Uyttenhove C., Pasterkamp G., Herbin O., Esposito B., Perez N., Yasukawa H., Van Snick J., Yoshimura A., Tedgui A., Mallat Z. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J. Exp. Med. 2009, 206:2067-2077.
42. Gisterå A., Robertson A.K., Andersson J., Ketelhuth D.F., Ovchinnikova O., Nilsson S.K., Lundberg A.M., Li M.O., Flavell R.A., Hansson G.K. Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci. Transl. Med. 2013, 5:196ra100.
43. Simon T., Taleb S., Danchin N., Laurans L., Rousseau B., Cattan S., Montely J.M., Dubourg O., Tedgui A., Kotti S., Mallat Z. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur. Heart J. 2013, 34:570-577.